STADA Arzneimittel AG

  • WKN: 725180
  • ISIN: DE0007251803
  • Land: Deutschland

Nachricht vom 11.07.2018 | 17:15

STADA Arzneimittel AG: Announcement of the results of the Tender Offer regarding the STADA-Bond 2015/2022:

DGAP-News: STADA Arzneimittel AG / Key word(s): Bond

11.07.2018 / 17:15
The issuer is solely responsible for the content of this announcement.

Investor News


Bad Vilbel, 11 July, 2018 - STADA Arzneimittel Aktiengesellschaft (the "Offeror") with its registered office at Stadastraße 2-18, 61118 Bad Vilbel, Federal Republic of Germany, hereby announces the results of its offer to purchase for cash (the "Tender Offer") any and all of its outstanding EUR 300,000,000 1.750% Notes due 2022, ISIN XS1213831362, Common Code 121383136, WKN A14KJP (the "Notes") from holders of the Notes ("Noteholders"). The Tender Offer was made pursuant to the terms and conditions set out in the tender offer memorandum dated as of 29 June 2018 (the "Tender Offer Memorandum").

Holders validly tendered Notes in an aggregate principal amount of EUR 15,656,000 for repurchase during the tender period, which began on 29 June 2018 and expired at 3 p.m., German time, on 10 July 2018.

The Offeror hereby announces that it will accept all such Notes validly tendered for repurchase under the terms and conditions set out in the Tender Offer Memorandum.

The Payment Date (as defined in the Tender Offer Memorandum) is expected to be 16 July 2018.
Afterwards, the Notes will still be outstanding in the aggregate amount of EUR 274,070,000.

Requests for information in relation to the Tender Offer can be directed to the Tender Agent:

Deutsche Bank Aktiengesellschaft
Taunusanlage 12
60325 Frankfurt am Main
Federal Republic of Germany
Attention: Trust and Agency Services
Telephone (UK): +44 20 7547 5000
Telephone (Germany): +49 69 910 35270

STADA Arzneimittel Aktiengesellschaft
Stadastraße 2 - 18
61118 Bad Vilbel
Federal Republic of Germany


The Tender Offer has not been made and will not be made, directly or indirectly, in or into, or by use of the mails of, or by any means or instrumentality of interstate or foreign commerce of, or of any facilities of a national securities exchange of, the United States. This includes, but is not limited to, facsimile transmission, electronic mail, telephone and the internet. The Notes may not be tendered in the Tender Offer by any such use, means, instrumentality or facility from or within the United States or by persons located or resident in the United States. Accordingly, copies of this announcement, the Tender Offer Memorandum and any other documents or materials relating to the Tender Offer are not being, and must not be, directly or indirectly, mailed or otherwise transmitted, distributed or forwarded (including, without limitation, by custodians, nominees or trustees) in or into the United States or to any persons located or resident in the United States. Any purported tender of Notes in the Tender Offer resulting directly or indirectly from a violation of these restrictions will be invalid and any purported tender of Notes made by a person located or resident in the United States, or any agent, fiduciary or other Intermediary acting on a non-discretionary basis for a principal giving instructions from within the United States will be invalid and will not be accepted.

The distribution of the Tender Offer Memorandum in certain jurisdictions may be restricted by law. Persons into whose possession the Tender Offer Memorandum comes are required by the Offeror and the Tender Agent to inform themselves about, and to observe, any such restrictions.

This announcement is neither an offer to purchase nor the solicitation of an offer to sell any of the securities described herein, nor shall there be any offer or sale of such securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. The Tender Offer was made solely pursuant to the Tender Offer Memorandum dated 29 June 2018.

This announcement must be read in conjunction with the Tender Offer Memorandum. This announcement and the Tender Offer Memorandum contain important information which should be read carefully before any decision is made with respect to the Tender Offer. If any Holder is in any doubt as to the action it should take, it is recommended that such Holder seek its own financial and legal advice, including as to any tax consequences, immediately from its stockbroker, bank manager, solicitor, accountant or other independent financial or legal adviser. Any individual or company whose Notes are held on its behalf by a broker, dealer, bank, custodian, trust company or other nominee or intermediary must contact such entity if it wishes to tender Notes in the Tender Offer. None of the Offeror or the Tender Agent makes any recommendation as to whether Noteholders should participate in the Tender Offer.

Neither the information contained in this announcement nor any other documents or materials relating to the Tender Offer have been approved by, or will be submitted for approval to, the Luxembourg Financial Services Authority (Commission de Surveillance du Secteur Financier) for purposes of a public offering or sale in the Grand Duchy of Luxembourg ("Luxembourg"). Accordingly, the Tender Offer may not be made to the public in Luxembourg, directly or indirectly, and neither the Tender Offer Memorandum, nor any other offering circular, prospectus, form of application, advertisement or other material relating to the Tender Offer may be distributed, or otherwise made available in, from, or published in, Luxembourg except in circumstances which do not constitute an offer of securities to the public, subject to prospectus requirements, in accordance with the Luxembourg Act of July 10, 2005 on prospectuses for securities, as amended, and implementing the Prospectus Directive, as amended.

The Offer is not subject to the German Securities Acquisition and Takeover Act (Wertpapiererwerbs- und Übernahmegesetzes (WpÜG)). The offer document has not been submitted to the German Federal Financial Supervisory Authority (Bundesanstalt für Finanzdienstleistungsaufsicht (BaFin)) for inspection, review and/or approval. The Offer will also not be subject to notification, registration, approval or permission procedures outside of Germany nor have any such procedures been applied or induced for or been granted. The publication, dispatch, distribution or dissemination of the offer document and other documents related to the Offer outside the Federal Republic of Germany may be subject to legal restrictions. The offer document and other documents related to the Offer may not be dispatched to or disseminated, distributed or published by third parties in countries in which this would be illegal. Depositary Banks may not publish, dispatch, distribute, or disseminate the offer document outside the Federal Republic of Germany unless in compliance with all applicable domestic and foreign statutory provisions. The Offer will be made solely pursuant to the terms and conditions of the Offer as laid out in the offer document.

The information contained in this announcement have not been approved by an authorised person for the purposes of section 21 of the Financial Services and Markets Act 2000. Accordingly, such documents and/or materials are not being distributed to, and must not be passed on to, the general public in the United Kingdom. The communication of such documents and/or materials as a financial promotion is only being made to those persons in the United Kingdom: (i) falling within the definition of investment professionals (as defined in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "Financial Promotion Order")), (ii) falling within Article 43(2) of the Financial Promotion Order, including existing members and creditors of the Company; or (iii) to whom it may otherwise lawfully be communicated (all such persons together being referred to as "Relevant Persons"). Any person in the United Kingdom who is not a Relevant Person should not act or rely on this document or materials or any of their content.

This announcement contains forward-looking statements and information that are necessarily subject to risks, uncertainties, and assumptions. No assurance can be given that the transactions described herein will be consummated or as to the terms of any such transactions. The Offeror assumes no obligation to update or correct the information contained in this announcement.

STADA Arzneimittel AG / Corporate Treasury / Frank Seiler / Stadastrasse 2-18 / 61118 Bad Vilbel - Germany / Tel.: +49 (0) 6101 603-4476 / Fax: +49 (0) 6101 603-3721 / E-mail:

Or visit us on the Internet at


11.07.2018 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at

show this

Interview im Fokus

PANTAFLIX: „Starkes Momentum“

Die PANTAFLIX AG ist kraftvoll in allen Geschäftsbereichen unterwegs und will neue Geschäftsfelder erschließen. „Unsere VoD-Plattform wächst rasant. Für PANTAFLIX eröffnen sich derzeit global gesehen Möglichkeiten, die es bis vor Kurzem noch gar nicht gab.“ Vorstandsvorsitzender (CEO) Stefan Langefeld und Chief Production Officer (CPO) Nicolas Paalzow erklären im die nächsten Schritte des Medienkonzerns.

GBC im Fokus

Homes & Holiday AG – Spezialist für Ferienimmobilien jetzt an der Börse

Seit 6.7. ist die Aktie der Home & Holiday AG nun an der Börse München im Qualitätssegment m:access gelistet. Der Handel auf Xetra und Frankfurt ist ebenfalls erfolgt. Damit ist der erste deutsche Ferien-Immobilien-Spezialist auf dem Parkett. Inklusive Pre-IPO-Kapitalerhöhung sind Homes & Holiday rund 5,8 Mio. Euro zur Wachstumsbeschleunigung zugeflossen. Der TOP-3 Makler aus Mallorca will nun noch stärker expandieren. Unser Research ist von den Zukunftsperspektiven überzeugt und empfiehlt die Aktie mit einem Kursziel von 4,83 Euro zum Kauf.

Aktuelle Research-Studie

curasan AG

Original-Research: curasan AG (von Montega AG): Halten

20. Juli 2018